• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Nitroquinolines and derivatives

Professional Introduction to 7-Chloro-6-nitroquinoline (CAS No. 58416-31-2)

7-Chloro-6-nitroquinoline, identified by its CAS number 58416-31-2, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This heterocyclic aromatic molecule has garnered considerable attention due to its versatile structural framework and potential applications in drug development. The presence of both chloro and nitro substituents on the quinoline backbone imparts unique reactivity and functionality, making it a valuable scaffold for synthesizing biologically active molecules.

The chemical structure of 7-Chloro-6-nitroquinoline consists of a quinoline ring system substituted at the 7-position with a chloro group and at the 6-position with a nitro group. This arrangement contributes to its distinct electronic properties, which are crucial for its interaction with biological targets. The nitro group, in particular, is known for its ability to participate in redox reactions, while the chloro group can serve as a handle for further chemical modifications. These features make the compound an attractive candidate for exploring novel therapeutic agents.

In recent years, there has been growing interest in quinoline derivatives as potential candidates for treating various diseases, including infectious diseases and cancer. The structural motif of 7-Chloro-6-nitroquinoline has been explored in several studies for its antimicrobial and antitumor properties. For instance, researchers have investigated its derivatives as inhibitors of bacterial enzymes and as agents that can induce apoptosis in cancer cells. The< strong>7-Chloro-6-nitroquinoline scaffold has shown promise in preclinical studies, demonstrating efficacy against certain resistant strains of bacteria and tumor cell lines.

One of the most compelling aspects of 7-Chloro-6-nitroquinoline is its synthetic accessibility. The compound can be readily prepared through well-established organic synthesis routes, allowing for easy modification and optimization. This flexibility is particularly valuable in drug discovery programs where rapid access to diverse chemical libraries is essential. Additionally, the< strong>CAS No. 58416-31-2 provides a unique identifier that ensures consistency and traceability throughout the research and development process.

The pharmacological profile of 7-Chloro-6-nitroquinoline has been extensively studied in various models. Research has highlighted its ability to interact with DNA and inhibit the activity of certain enzymes involved in cellular metabolism. These interactions are often mediated by the electron-withdrawing nature of the nitro and chloro groups, which modulate the electronic environment of the quinoline ring. Such properties are particularly relevant in developing drugs that target specific biological pathways.

Moreover, the< strong>7-Chloro-6-nitroquinoline derivative has been explored for its potential role in chemoprevention. Studies suggest that it may interfere with signaling pathways that promote cancer cell growth and survival. By modulating these pathways, the compound could potentially reduce the risk of tumor development or slow down disease progression. These findings have opened up new avenues for further investigation into its therapeutic applications.

In conclusion, 7-Chloro-6-nitroquinoline (CAS No. 58416-31-2) is a multifaceted compound with significant potential in pharmaceutical research. Its unique structural features and biological activities make it a valuable tool for developing novel drugs targeting various diseases. As research continues to uncover new applications for this molecule, it is likely to remain a cornerstone in medicinal chemistry efforts aimed at improving human health.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)